What We're Reading: Page 101
Industry reads hand-picked by our editors
Sep 30, 2022
-
Reuters
Eisai’s trial success raises hope for Alzheimer’s prevention
-
The New York Times
China Gets Its First mRNA Covid Vaccine Approval — in Indonesia
-
FiercePharma
Intercept’s Ocaliva fails its 2nd NASH trial
Sep 29, 2022
-
The Boston Globe
2 Boston-area scientists win prestigious Lasker Awards for cell research
-
Bloomberg
Global Monkey Shortage for Experiments Boosts China’s Vaccine Development
-
The Wall Street Journal
SK Capital Buys Generic-Drug Firm Founded by Murdered Canadian Billionaire
-
Nature
‘Bionic pancreas’ tames diabetes blood-sugar spikes
Sep 28, 2022
Sep 27, 2022
Sep 26, 2022
Sep 23, 2022
-
The Financial Times
Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory
-
Chemical & Engineering News
Pharma companies race to develop mRNA vaccines for influenza
-
Evaluate Vantage
Novartis has the most new approvals, but Lilly’s are worth more
-
The Wall Street Journal
Moderna Covid-19 Booster Shortage Leads to Fewer Appointments at Pharmacies
Sep 22, 2022
-
Reuters
Novartis to prioritise U.S. market, unfazed by drug pricing pushback
-
The Economist
Fixing the brain
-
Boston Business Journal
Cambridge City Council weighs proposal to ban new labs in Harvard Square, Central Square
-
Washington Post
How to take a pill: Our posture affects how we digest pills, study says
Previous
